SecBot SecBot
SECBOTREPLAY Home › Report › QURE

QURE · uniQure announced that the FDA has agreed the 3-year analysis from the…

uniQure N.V. · 8-K filed Jun 17, 2026 at 07:10 ET

At the news

BULLISHIMPACT 8/10

8-K filed Jun 17, 2026 at 07:10 ET

uniQure announced that the FDA has agreed the 3-year analysis from the Phase I/II study of AMT-130 in Huntington's disease can serve as the primary basis of a BLA for accelerated approval. The company intends to submit the BLA in Q3 2026. This is a major regulatory milestone for a gene therapy targeting a currently untreatable neurodegenerative disease with no approved disease-modifying therapies, de-risking the path to market for a pivotal pipeline asset.

  • FDA communicated during a Type B meeting that 3-year Phase I/II data are acceptable as primary basis for BLA for accelerated approval of AMT-130 in Huntington's disease.
  • Company plans to submit the BLA in the third quarter of 2026.
  • FDA seeks alignment on confirmatory study design prior to BLA submission, including consideration of a concurrent standard-of-care control instead of a sham procedure.
  • AMT-130 has RMAT, Breakthrough Therapy, and Fast Track designations from the FDA.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access